Developing innovative treatments for KRAS-driven cancers

Silexion Therapeutics Corp. (NASDAQ: SLXN) is a clinical-stage biopharmaceutical company developing RNA interference (RNAi) treatments for KRAS-driven cancers, including pancreatic cancer. Its lead candidate, SIL204, is being investigated in a Phase 2/3 clinical program for locally advanced pancreatic cancer.

Company Profile

Silexion Therapeutics combines cutting-edge science, advanced technologies, and a passion for innovation to address the significant unmet medical needs in pancreatic cancer treatment.

Silexion is currently investigating SIL204, a pan-KRAS RNA silencing therapy, in a Phase 2/3 clinical program for locally advanced pancreatic cancer.

Core Technologies

RNA interference harnesses natural biological mechanisms to silence cancer-causing genes before proteins are produced.

The Phase 2/3 trial evaluates SIL204 in combination with standard-of-care chemotherapy, versus chemotherapy alone. Its integrated regimen combines direct endoscopic ultrasound (EUS)-guided intratumoral administration with subcutaneous abdominal injections designed to provide systemic exposure and address potential micro-metastases.

SIL204

SIL204 is Silexion's lead, second-generation small interfering RNA (siRNA) candidate, currently undergoing Phase 2/3 clinical evaluation for locally advanced pancreatic cancer.

Latest Press Releases